Trial reportJournal of the American Heart Association2025
Apolipoprotein E Plasma Concentrations Are Predictive of Recurrent Strokes: Insights From the SPARCL Trial.
Trial report in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Mechanistic explanation for the different statin response according to APOE genotypes.British journal of clinical pharmacology · 2026Article
- Alterations of Apolipoprotein A1, E, and J Genes in the Frontal Cortex in an Ischemic Model of Alzheimer's Disease with 2-Year Survival.International journal of molecular sciences · 2025Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn the SPARCL (Stroke Prevention by Aggressive Reduction in Cholesterol Levels) trial, atorvastatin (80 mg per day) was compared with placebo in patients with recent stroke or transient ischemic attack and no known coronary artery disease. Given the central role of apoE (apolipoprotein E) in lipoprotein metabolism and in the central nervous system, we assessed the contribution of apoE to subsequent cerebrovascular and cardiovascular events in this trial. METHODS AND
resultsApoE concentrations and major isoforms (E2/E3/E4) were determined by liquid-chromatography high resolution mass-spectrometry in plasma samples collected at baseline from 4348 SPARCL participants. Patients in the lowest quartile were compared with those in the highest quartiles of apoE concentrations. Multivariable-adjusted hazard-ratios (HR) and 95% CIs were calculated using Cox proportional hazards regression models. We found a significant association between low apoE concentrations and the risk of recurrent strokes or cerebrovascular events (HR, 1.401 [95% CI, 1.154-1.701],
conclusionsLow apoE concentrations are predictive of recurring cerebrovascular events in patients with a history of stroke or transient ischemic attack. REGISTRATION: URL: https://www.clinicaltrials.gov; Identifier: NTC00147602.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.